Hansa Biopharma — November 2021
-
Sorry, dette link :-),,https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/97808_HNSA20211013_1.pdf
-
Ja, man skal vist passe lidt på når man dropper et link
file:///Users/christopherarzrouni/Downloads/HNSA20211013.pdf
Anders Fogh Rasmussens havde også lidt pdf-udfordringer med sin nytårstale for år tilbage.
Statsministeriet strammer it-sikkerheden
Statsministeriet har strammet it-sikkerheden. Det sker efter afsløringen af, at Anders Fogh Rasmussens nytårstale er skrevet i et dokument, der oprindeligt blev oprettet af den erhvervsjuridiske chef i Dansk Industri.
DR (www.dr.dk)
-
Hansa Biopharma announces it has confidentially submitted a draft registration statement on Form F-1 to the U.S. SEC relating to a potential U.S. IPO
-
Da Genmab gjorde det samme var mange skeptiske. Det viste sig bare at være en fantastisk beslutning. Genmab gjorde det dog på et helt andet tidspunkt. Vi har set andre danske biotek selskaber ala Hansa's størrelse der har haft blandede resultater med dette.
-
Hansa Biopharma AB: Hansa Biopharma avser att initiera en fas 3-studie med imlifidase för behandling av anti-GBM-sjukdom efter framgångsrikt rådgivningsmöte med FDA i USA
-
Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-Glomerular Basement Membrane (anti-GBM) disease after successful pre-IND meeting with U.S. FDA
(11/15/2021)
-
"Den nu avslutade fas 2-studien visade att två tredjedelar av patienterna inte behövde dialys sex månader efter behandling med imlifidase. Detta positiva resultat validerar imlifidase som en potentiell behandling av allvarliga IGG-medierade autoimmuna sjukdomar, skriver Hansa Biopharma."
Super!
-
Er MSE ved at lukke deres shorts? De har også bombet kursen langt ned over lang tid, og begynder måske at lukke nogle shorts. Lad os se, de giver nok ikke så let op.
-
Så shorter MSE igen....møgirriterende som de bomber Hansa.
-
Hansa Biopharma; FDA opens the door for the next pivotal Phase 3 study
-
Uddrag:
"In our view, Hansa Biopharma’s ability to progress the progress of the anti-GBM opportunity for the imlifidase platform is distinctly positive. This follows a successful pre-IND meeting with the FDA. Recently we have seen several FDA delays in this sector, and Hansa’s ability to timely progress this candidate to the third pivotal Phase 3 trial is an achievement."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind